Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial

Mostra altre versioni (1)

<p><strong>Background</strong> Cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection continue to rise in the Arabian Peninsula 7 years after it was first described in Saudi Arabia. MERS-CoV poses a significant risk to public health security because of an absenc...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Folegatti, PM, Bittaye, M, Flaxman, A, Ramos Lopez, F, Bellamy, D, Mair, C, Makinson, R, Sheridan, J, Boyd, A, Tran, N, Silman, D, Poulton, I, Datoo, M, Marshall, J, Themistocleous, Y, Lawrie, A, Roberts, R, Berrie, E, Lambe, T, Hill, A, Ewer, K, Gilbert, S, Et al.
Natura:	Journal article
Lingua:	English
Pubblicazione:	Elsevier 2020

Documenti analoghi

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial
di: Folegatti, PM, et al.
Pubblicazione: (2020)

Safety and immunogenicity of a replication deficient simian adenoviral vectored chikungunya vaccine: A phase I, first-in-human, dose escalation trial
di: Folegatti, PM, et al.
Pubblicazione: (2019)

Safety and immunogenicity of adenovirus and poxvirus vectored vaccines against a Mycobacterium avium complex subspecies
di: Folegatti, P, et al.
Pubblicazione: (2021)

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
di: Folegatti, P, et al.
Pubblicazione: (2019)

A single dose of ChAdOx1 Chik vaccine induces neutralising antibodies against four chikungunya virus lineages in a phase 1 clinical trial
di: Folegatti, P, et al.
Pubblicazione: (2021)

Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies
di: Pedro M. Folegatti, et al.
Pubblicazione: (2021-03-01)

Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured onthe AGE1.CR.pIX Avian Cell Line
di: Folegatti, P, et al.
Pubblicazione: (2019)

CMV-associated T cell and NK cell terminal differentiation does not impact immunogenicity of ChAdOx1 vaccination
di: Sharpe, HR, et al.
Pubblicazione: (2022)

Safety and immunogenicity of ChAdOx1 MERS Vaccine Candidate in Healthy Middle Eastern Adults: a dose-escalation, open-label, non-randomised, phase 1b trial
di: Bosaeed, M, et al.
Pubblicazione: (2021)

A three-antigen Plasmodium falciparum DNA prime—Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults
di: Sklar, MJ, et al.
Pubblicazione: (2021)

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
di: Pedro M. Folegatti, et al.
Pubblicazione: (2019-05-01)

Deep immune phenotyping and single-cell transcriptomics allow identification of circulating TRM-like cells which correlate with liver-stage immunity and vaccine-induced protection from malaria
di: Noe, A, et al.
Pubblicazione: (2022)

Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line
di: Pedro M. Folegatti, et al.
Pubblicazione: (2019-03-01)

Clinical development of viral vectored vaccines against MERS-COV
di: Ewer, K, et al.
Pubblicazione: (2018)

Efficacy and safety of a modified Vaccinia Ankara-NP+M1 vaccine combined with QIV in people aged 65 and older: a randomised controlled clinical trial (INVICTUS)
di: Butler, C, et al.
Pubblicazione: (2021)

CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination
di: Hannah R. Sharpe, et al.
Pubblicazione: (2022-03-01)

A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial
di: Pedro M. Folegatti, et al.
Pubblicazione: (2021-07-01)

Safety and immunogenicity of varied doses of R21/Matrix-M™ vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya [version 1; peer review: 2 approved]
di: Omar Ngoto, et al.
Pubblicazione: (2023-10-01)

Viral vectors as vaccine platforms: from immunogenicity to impact
di: Ewer (nee Russell), K, et al.
Pubblicazione: (2016)

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
di: Folegatti, PM, et al.
Pubblicazione: (2020)

Deep Immune Phenotyping and Single-Cell Transcriptomics Allow Identification of Circulating TRM-Like Cells Which Correlate With Liver-Stage Immunity and Vaccine-Induced Protection From Malaria
di: Andrés Noé, et al.
Pubblicazione: (2022-02-01)

A Phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS
di: De Barra, E, et al.
Pubblicazione: (2014)

Prime and target immunization protects against liver-stage malaria in mice
di: Gola, A, et al.
Pubblicazione: (2018)

Methods for measuring T-cell memory to vaccination: from mouse to man
di: Flaxman, A, et al.
Pubblicazione: (2018)

Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors.
di: Sheehy, S, et al.
Pubblicazione: (2012)

Safety and immunogenicity of the novel plasmodium falciparum blood-stage vaccine RH5.1/AS01B in a phase I/IIA clinical trial
di: Minassian, AM, et al.
Pubblicazione: (2017)

Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African children and infants
di: Bliss, C, et al.
Pubblicazione: (2016)

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
di: Barrett, J, et al.
Pubblicazione: (2020)

Efficacy and Safety of a Modified Vaccinia Ankara-NP+M1 Vaccine Combined with QIV in People Aged 65 and Older: A Randomised Controlled Clinical Trial (INVICTUS)
di: Chris Butler, et al.
Pubblicazione: (2021-08-01)

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
di: Flaxman, A, et al.
Pubblicazione: (2021)

Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M
di: Venkatraman, N, et al.
Pubblicazione: (2017)

Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1.
di: Berthoud, T, et al.
Pubblicazione: (2011)

Safety and immunogenicity of the novel plasmodium falciparum blood-stage vaccine chad63-mva rh5 in a phase ia clinical trial
di: Payne, R, et al.
Pubblicazione: (2017)

Expansion of CD57+KLRG1+ T cells is associated with reduced vaccine responses in CMV+ young adults
di: Bowyer, G, et al.
Pubblicazione: (2020)

A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS.
di: Eoghan de Barra, et al.
Pubblicazione: (2014-01-01)

High level efficacy in humans of a next-generation plasmodium falciparum anti-sporozoite vaccine: R21 in Matrix-M (TM) adjuvant
di: Venkatraman, N, et al.
Pubblicazione: (2017)

Real de-escalation or escalation in disguise?
di: Maggie Banys-Paluchowski, et al.
Pubblicazione: (2023-06-01)

Safety and immunogenicity of malaria vectored vaccines given with routine EPI vaccines in Gambian infants and neonates: a randomized controlled trial
di: Mensah, V, et al.
Pubblicazione: (2017)

Vaccines against Ebola virus
di: Venkatraman, N, et al.
Pubblicazione: (2017)

Methods for Measuring T-Cell Memory to Vaccination: From Mouse to Man
di: Amy Flaxman, et al.
Pubblicazione: (2018-07-01)